A Phase 2 interventional study of Niacin and Placebo for Niacin in Septic Shock, sponsored by Seoul National University Hospital. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Seoul National University Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Shock, Septic with a site in Korea, Republic of — 3 open to participants now, 3 under way, none of them phase 3. Shock, Septic · Korea, Republic of.
Among the 12 studies in Shock, Septic with a site in Korea, Republic of, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 2, and was the 12th registered.
1,080 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.
Browse Shock, Septic studies →3 of the 12 studies in Shock, Septic with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 19+
Asan Medical Center · Sites in Korea, Republic of
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 137 Shock, Septic studies recruiting now, 102 (74%) set no upper age limit and 19 (14%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 148 is above the median of 80 across 636 interventional studies indexed under Shock, Septic.
Median enrollment 148 across the 11 interventional studies, 360 across the 1 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 10 most frequent:
Seoul National University Hospital is the lead sponsor of 1,902 studies on the registry; 276 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Seoul National University Hospital has 2 studies filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
2 of the studies in Shock, Septic with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07539883Seoul National University Bundang HospitalEffect of oXiris Hemofilter Use in Septic Shock: A Multicenter Retrospective Cohort Study | 2026-12-31 |
| NCT05148286Asan Medical CenterAlbumin and Crystalloid Administration in Septic Shock | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Shock, Septic with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will test whether adding niacin, a form of vitamin B3, and selenium, a mineral, to standard treatment improves organ function in adults with septic shock. It will also assess the safety of this combination.
The study plans to enroll 148 patients aged 19 years or older in the emergency intensive care unit at Seoul National University Hospital in South Korea. Participants will be assigned by chance to one of two groups, with an equal chance of receiving either niacin plus selenium or placebo infusions. The placebo infusions use saline and glucose (sugar) solutions and do not contain the study drugs. All participants will receive standard treatment for septic shock.
Study treatments will be given through a vein twice a day during the first week of hospitalization. Participants and the researchers assessing outcomes will not know which treatment each participant receives. The study pharmacist and a designated team that prepares and gives the infusions will know the treatment assignments.
The main comparison will be organ function on the seventh day of hospitalization, measured using the Sequential Organ Failure Assessment (SOFA) score. This score measures how well several organs are working. Researchers will also compare survival at 28 and 90 days, time spent in intensive care, and time on a breathing machine. Blood samples will be collected at enrollment, approximately 72 hours later, and on study day 7 to measure niacin and selenium levels and biomarkers related to antioxidant activity and oxidative stress. Possible side effects will be monitored through daily assessments and blood tests.
Oxidative stress and dysregulated inflammatory responses contribute to tissue injury and organ dysfunction in septic shock. The rationale for combining niacin and selenium is to enhance intracellular antioxidant defenses through complementary effects on the glutathione redox cycle.
Preclinical experiments showed that niacin increased glutathione reductase activity and selenium increased glutathione peroxidase activity. Combined treatment reduced hydrogen peroxide levels, attenuated lung injury, and improved survival in rat models of sepsis. These findings provide a biological basis for evaluating the combination as an adjunctive treatment in patients with septic shock.
The study hypothesis is that combined niacin and selenium treatment during the acute phase of septic shock may reduce oxidative and inflammatory injury and thereby limit organ dysfunction. This study is intended to provide preliminary clinical evidence on efficacy and safety and to inform the planning of a subsequent multicenter trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Infection-related organ dysfunction with a Sequential Organ Failure Assessment (SOFA) score of 2 or greater.
Sepsis-induced hypotension requiring vasopressors to maintain a mean arterial pressure of 65 mmHg or higher.
A blood lactate concentration of 2 mmol/L or higher despite administration of 30 mL/kg of intravenous crystalloid fluid. If this volume cannot be administered because of pulmonary edema, heart failure, chronic renal failure, or other clinical limitations, the maximum clinically tolerated volume of crystalloid fluid must have been administered.
Written provided by the participant or an authorized representative.
Informed consent and randomization completed within 24 hours after the diagnosis of septic shock.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive intravenous niacin plus selenium every 12 hours during the first week of hospitalization, in addition to standard care for septic shock.
Drug: Niacin · Drug: Selenium
Participants receive intravenous placebo infusions of 0.9% sodium chloride and 5% dextrose every 12 hours during the first week of hospitalization, in addition to standard care for septic shock.
Drug: Placebo for Niacin · Drug: Placebo for Selenium
Niacin (nicotinic acid) is supplied by Christmas Co., Ltd. (South Korea) as V-Tree Inj., a solution for injection containing 50 mg of niacin per 1 mL ampoule. A dose of 100 mg will be diluted with 0.9% sodium chloride solution to a final volume of 50 mL and administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization.
Participants receive 50 mL of 0.9% sodium chloride solution as the placebo for niacin. The solution is administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization.
Selenium is supplied as selenase T pro injectione (biosyn Arzneimittel GmbH, Germany), a solution for injection containing 500 micrograms of selenium as sodium selenite pentahydrate per 10 mL vial (50 micrograms/mL). A dose of 5 micrograms/kg of selenium will be diluted with 5% dextrose solution to a final volume of 50 mL and administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization.
Participants receive 50 mL of 5% dextrose solution as the placebo for selenium. The solution is administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization.
Sequential Organ Failure Assessment (SOFA) Score on Hospital Day 7
Total Sequential Organ Failure Assessment (SOFA) score assessed on hospital day 7. The SOFA score evaluates six organ systems: respiratory, coagulation, liver, cardiovascular, central nervous system, and renal. Each component is scored from 0 to 4, giving a total score of 0 to 24; higher scores indicate more severe organ dysfunction. The day-7 score will be compared between groups using analysis of covariance, with adjustment for the SOFA score at admission.
Time frame: Hospital day 7
28-Day Survival
Survival will be assessed from hospital admission, defined as hospital day 0, through day 28. The probability of survival at day 28 will be estimated using the Kaplan-Meier method.
Time frame: From hospital admission (hospital day 0) through day 28
90-Day Survival
Survival will be assessed from hospital admission, defined as hospital day 0, through day 90. The probability of survival at day 90 will be estimated using the Kaplan-Meier method.
Time frame: From hospital admission (hospital day 0) through day 90
Length of Intensive Care Unit Stay
Length of stay in the intensive care unit, measured in days, during follow-up through hospital day 90.
Time frame: From hospital admission (hospital day 0) through hospital day 90
Duration of Mechanical Ventilation
Duration of mechanical ventilation, measured in days, during follow-up through hospital day 90.
Time frame: From hospital admission (hospital day 0) through hospital day 90
Pharmacologic, Antioxidant, and Mechanistic Biomarkers
Blood samples will be analyzed to assess the biological effects of niacin and selenium treatment, including circulating niacin and selenium levels and biomarkers related to antioxidant activity, redox balance, and oxidative stress. Planned analyses include glutathione reductase activity, glutathione peroxidase activity, and hydrogen peroxide levels.
Time frame: At enrollment, 72 hours (±6 hours), and day 7
Plan to share: Yes — De-identified individual participant data that underlie the results reported in the primary publication may be shared with qualified researchers upon reasonable request, subject to review and approval by the principal investigator and applicable institutional and ethical requirements. Data will be shared only in a manner that protects participant confidentiality and privacy.
Supporting information: Study protocol, Statistical analysis plan
Time frame: De-identified individual participant data and supporting information will be available beginning 6 months after publication of the primary study results and for 3 years thereafter.
Access criteria: De-identified individual participant data that underlie the results reported in the primary publication, together with the study protocol and statistical analysis plan, may be made available to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the principal investigator and must comply with applicable institutional and ethical requirements. Approved data will be provided through a secure data-sharing method after execution of any required data use agreement.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Apr 2028, 17 months later.
Of 36 non-industry phase 2 interventional studies under Shock, Septic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's planned 17 months is below that.
Counting every sponsor, half of 41 studies reached it within 29 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Niacin · Selenium
Seoul National University Hospital →